Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D

Medicine & Life Sciences

• Medicare Part D 100%
• Cost Sharing 97%
• Hematinics 89%
• Myelodysplastic Syndromes 32%
• Health Expenditures 29%
• Physicians' Offices 28%
• Income 17%
• Medicare Part A 12%
• Medicare Part B 11%
• Erythropoietin 7%
• Medicare 7%
• Anemia 6%
• Prescriptions 5%
• Motivation 5%
• Costs and Cost Analysis 4%
• Injections 4%

Social Sciences

• cost sharing 86%
• subsidy 63%
• medication 55%
• low income 50%
• physician 48%
• costs 36%
• incentive 16%
• management 10%